Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

APA: High Rate of Sustained Remission With Celexa (Citalopram HBr) Treatment For Depression NEW ORLEANS, LA -- May 10, 2001 -- Fifty-nine percent of patients with depression had no significant symptoms after 20 weeks of therapy when treated with citalopram HBr (Celexa™), according to a pooled analysis of four long-term studies with a total of 810 patients. Citalopram is a selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of depression. The study was presented at the American Psychiatric Association's annual meeting. "Across the four studies, 59 percent of patients treated with citalopram met the strictest therapeutic standard of complete and sustained remission, which means that there were no signs of depression," said Michael Thase, M.D., professor of psychiatry at the University of Pittsburgh School of Medicine. The full remission of symptoms after 20 weeks of therapy in the citalopram-treated patients far exceeded the standard description of full-sustained remission, which is defined by DSM-IV, psychiatry's diagnostic manual, as a period of at least two months in which there are no significant symptoms. Additionally, the evaluation of citalopram's efficacy in this analysis was substantially more rigorous than assessments sometimes used in clinical trials of antidepressants (e.g., 50 percent or more reduction in acute, short-term symptoms of patient response). "Full remission should be the goal of antidepressant therapy, rather than short-term response, because full remission is associated with better psychosocial functioning and reduces the risk of relapse," said Dr. Thase. "Most of the patients treated with citalopram in these four studies achieved full remission." A total of 810 patients with major depressive disorder (MDD) participated in the four studies, which were analyzed retrospectively. The studies included in-patients and out-patients from a range of age groups, with at least 230 patients age 65 or older. Treatments consisted of both open-label and double blind dosing with citalopram for periods ranging from 20 to 28 weeks. Across all four studies, an average of 59 percent of patients achieved remission, with sustained remission rates ranging from 53 to 72 percent in the studies. Citalopram was well-tolerated across all four trials. The side effects most commonly reported were headache, nausea, diarrhea and sleepiness. Citalopram has been shown to be safe and effective in many large-scale clinical trials involving patients with mild-to-moderate depression. Because citalopram has little or no potential to inhibit the metabolism of other drugs, it may be an especially useful antidepressant for older or medically complicated patients. As with all SSRIs, citalopram should not be taken together with monoamine oxidase inhibitors. SOURCE: University of Pittsburgh E-mail this page to a friend or colleague! To print, use this version